Conference Call to be Held on October 16th
SAN DIEGO, Oct. 10 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) announced today that the company will release its fourth quarter and year end results on or before Wednesday, October 15, 2008, and will subsequently host a conference call on Thursday, October 16, 2008, commencing at 4:30 PM ET. The conference call will consist of prepared remarks from management and will be available over the Internet via live web cast at http://www.purebio.com. Shareholders can submit questions for the conference call via the Contact Investor Relations section of the company web page at http://www.purebio.com.
The conference call will also be accessible by telephone at 800-309-1352 (no passcode required) and participants are advised to dial-in at least five minutes before the scheduled start time. The replay of the conference call will be available for seven days by telephone at 888-203-1112 or 719-457-0820 using passcode 3067874. The webcast will be archived for a period of 90 days at http://www.purebio.com.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. These statements
are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements inherently
involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, acceptance
of the Company's current and future products and services in the
marketplace, the ability of the Company to develop effective new products
and receive regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, and other risks detailed in the
Company's periodic report filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or
changes after the date of this release.
Paul G. Henning, Vice President
212 554 5462
|SOURCE PURE Bioscience|
Copyright©2008 PR Newswire.
All rights reserved